ScholarIQanswers from OpenAlex

Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling.

PaperCitations, authors & open-access status

Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. have?

ScholarIQcitation count

Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. has 20 citations in the OpenAlex counts ScholarIQ stores.

When was Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. published?

ScholarIQyear

Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. has 2020 year in the ScholarIQ index.

Open the OpenAlex record →

What is the open-access status of Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling.?

ScholarIQoa status

Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. has green oa status in the ScholarIQ index.

Open the OpenAlex record →

What is the PMID of Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling.?

ScholarIQpmid

The PMID for Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. is on the source record.

Open the PMID →

What is the OpenAlex record for Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling.?

ScholarIQopenalex

The OpenAlex for Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. is on the source record.

Open the OpenAlex →

Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling.

How many citations does Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling. have?

When was Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling. published?

What is the open-access status of Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling.?

What is the PMID of Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling.?

What is the OpenAlex record for Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling.?

Related on ScholarIQ